Comparing Semaglutide, Tirzepatide, and Retatrutide
- Semaglutide is a GLP-1 receptor agonist that mainly supports appetite control, fullness, slower gastric emptying, and blood sugar regulation.
- Tirzepatide acts on both the GIP and GLP-1 pathways, which may explain why it has shown greater average weight loss than semaglutide in head-to-head obesity trials.
- Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors, but it’s not FDA-approved.
What Are Semaglutide, Tirzepatide, and Retatrutide?
Semaglutide, tirzepatide, and retatrutide are injectable medications that act on hormone pathways involved in appetite, fullness, blood sugar regulation, and weight management.
Semaglutide is a GLP-1 receptor agonist. That means it works mainly through the GLP-1 pathway, which helps increase fullness, reduce appetite, slow stomach emptying, and support blood sugar control. FDA-approved semaglutide options include Wegovy for chronic weight management and Ozempic for type 2 diabetes.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works on two incretin pathways instead of one, which may help explain why it has shown strong weight loss results in clinical trials. FDA-approved tirzepatide options include Zepbound for chronic weight management and Mounjaro for type 2 diabetes.
Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. It is getting attention because early and emerging clinical trial data suggest significant weight loss potential, but it’s not FDA-approved and shouldn’t be used outside appropriate medical research or future approved treatment pathways.
The Difference Between Single, Dual, and Triple Agonists
The main difference is how many hormone receptors each medication activates.
| Medication | Type | Receptors targeted | What that means |
| Semaglutide | Single agonist | GLP-1 | Primarily targets appetite, fullness, slower stomach emptying, and blood sugar regulation. |
| Tirzepatide | Dual agonist | GIP + GLP-1 | Adds GIP activity, which may enhance metabolic effects beyond GLP-1 alone. |
| Retatrutide | Triple agonist | GIP + GLP-1 + glucagon | Adds glucagon receptor activity, which researchers are studying for effects on energy expenditure, fat metabolism, and liver fat. |
GLP-1 activity is most closely tied to appetite control, fullness, slower gastric emptying, and blood sugar regulation. This is why people often associate GLP-1 medications with reduced hunger, less food noise, and feeling full sooner.
GIP activity may add another layer of metabolic support. Researchers are still studying exactly how it contributes to weight loss, but it appears to work differently from GLP-1 and may help explain why dual-agonist medications can produce stronger average results for some patients.
Glucagon receptor activity may influence energy use, liver metabolism, and fat breakdown, but it also requires careful study because glucagon can affect heart rate and other metabolic systems. Retatrutide is still investigational and has not been found safe and effective by the FDA.
How The Weight Loss Results Compare So Far
The strongest comparison is not perfect because these medications have not all been studied in the same way. Semaglutide and tirzepatide have FDA-approved versions for weight management, while retatrutide is still investigational. Still, published trial data gives us a useful snapshot of how the results compare so far.
| Medication | Receptors Targeted | Published Weight Loss Data | Current Status |
| Semaglutide | GLP-1 | STEP 1 showed about 14.9% mean weight loss at 68 weeks. [1] | FDA-approved versions exist for weight management and diabetes, depending on the brand. |
| Tirzepatide | GIP + GLP-1 | SURMOUNT-5 showed 20.2% weight loss with tirzepatide vs 13.7% with semaglutide at 72 weeks. [2] | FDA-approved versions exist for weight management and diabetes, depending on the brand. |
| Retatrutide | GIP + GLP-1 + glucagon | Phase 2 data showed up to 24.2% mean weight loss at 48 weeks. [3] | Investigational, not FDA-approved. |
Sources:
[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
[2] Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2416394.
[3] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
Why You Cannot Compare Doses One-To-One
Semaglutide, tirzepatide, and retatrutide are not interchangeable milligram-for-milligram. Even when they are used for similar goals, they are different molecules with different receptor activity, dosing schedules, titration plans, side effect profiles, and levels of clinical evidence.
This is why a dose of semaglutide does not “equal” a specific dose of tirzepatide or retatrutide. A higher milligram number doesn’t automatically mean a stronger or better effect, because each medication interacts with the body differently.
This matters most when people are switching medications or reading online dose-conversion charts. Those charts can be misleading because they oversimplify medications that are not designed to be converted directly. Wegovy and Zepbound, for example, have their own separate prescribing schedules and dose-escalation approaches, and retatrutide is still investigational with ongoing research around dose response, safety, and efficacy.
What About Appetite, Food Noise, and Cravings?
For many patients, the biggest difference is not just the number on the scale. It’s how the medication changes hunger, fullness, cravings, and what many people call “food noise.”
Food noise is not a formal medical diagnosis, but it’s a helpful way to describe constant thoughts about food, cravings, snacking urges, or feeling like appetite is always taking up mental space. GLP-1 based medications may reduce appetite by helping people feel full sooner, stay full longer, and experience less drive to eat.
Semaglutide can feel very appetite-focused for some patients because it works strongly through the GLP-1 pathway. Tirzepatide may feel different because it adds GIP activity, and some patients report a different balance of appetite control, fullness, and tolerability. Retatrutide may eventually show its own pattern because of the added glucagon pathway, but it’s too early to make firm real-world claims because it is not FDA-approved.
The most important point is that the response varies. Some people do very well on semaglutide. Others respond better to tirzepatide. Some people lose weight but struggle with nausea, constipation, reflux, or appetite suppression that feels too strong.
The best option is not always the one with the highest trial average. It’s the one that works safely and sustainably for the individual.
Side Effects And Tolerability
Side effects can happen with all three medications, but the pattern, intensity, and timing can vary by person, dose, and medication.
Common side effects may include:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Reflux or indigestion
- Abdominal discomfort
- Fatigue
- Appetite suppression that feels too strong
- Dehydration risk if eating or drinking drops too much
These effects are often most noticeable when starting treatment or increasing the dose. That is why gradual titration matters.
Tolerability matters just as much as weight loss. A medication may look stronger in a study, but if it causes nausea, constipation, reflux, dehydration, or appetite suppression that feels unsustainable, it may not be the best fit.
A provider can often improve tolerability by adjusting the plan, such as slowing dose increases, reviewing meal size, supporting hydration, managing constipation early, or considering a medication switch when appropriate.
Why Medical Guidance Matters More Than Online Comparisons
Semaglutide, tirzepatide, and retatrutide show how quickly medical weight loss is evolving, but the right choice is not based on trial averages or online comparisons alone. It depends on your health history, goals, side effect tolerance, appetite patterns, medication access, and long-term plan.
The most effective path is the one that your body can tolerate, respond to, and sustain over time. At Kintsu MedSpa & Wellness, medical weight loss is personalized and provider-guided, with support for choosing the right starting option, adjusting when needed, and managing side effects along the way.
Contact us to schedule a weight loss consultation and take the next step toward a plan built for safe, sustainable progress.